Evidence map›Paper›PMID 41530382›Full record

Trial reportNature medicine2026

A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial.

C Kulkarni, T Fardeen, J Gubatan, J Ye, K Jarr, E Dickson, H Jang, M Temby, A Patel, Y Jiang and 20 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04147585 (Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04147585 nacompletednot on this map

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

TypeinterventionalSponsorStanford UniversityRan2019 to 2024Enrolled86ConditionsInflammatory Bowel Diseases, Crohn Disease, Diet ModificationArmsIntermittent Reduced Calorie Diet (IRCD)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

C Kulkarni *Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
T Fardeen *Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6050-740X
J GubatanDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6037-2883
J YeDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
K JarrDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
E DicksonDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
H JangDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0009-0001-4124-9908
M TembyDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
A PatelDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Y JiangDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
G SinghDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
K KeyashianDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
S StreettDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
E HoDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
G BarberDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
S SinghDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
D LimsuiDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
N AnaiziGastroenterology, Stanford Health Care, Stanford, CA, USA.
L BeckerDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8736-0257
S P SpencerDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7328-5399
D MehrishDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
D PerelmanDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3335-1950
V D LongoLongevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0946-7534
V CharuDepartment of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.
J F AshouriRosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8405-7503
M M DavisMicrobiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6868-657X
A HabtezionDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
J L SonnenburgMicrobiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
C GardnerStanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7596-1530
S R SinhaDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA. sidsinha@stanford.edu.ORCID http://orcid.org/0000-0001-5104-6410

Funding

Stanford Center for Clinical and Translational Research and EducationUM1TR004921 · NCATS · STANFORD UNIVERSITY · PI MANISHA DESAI, DEAN W FELSHER · 2024 to 2026
$30.1M
TRAINING GRANT IN ACADEMIC GASTROENTEROLOGYT32DK007056 · NIDDK · STANFORD UNIVERSITY · PI Natalie J. Torok · 1986 to 2026
$6.5M
Impact of Diet on Intestinal Microbiota-Host DynamicsR01DK085025 · NIDDK · STANFORD UNIVERSITY · PI JUSTIN L SONNENBURG · 2010 to 2026
$6.4M
Defining Small Intestinal Microbial Landscapes To Improve Therapeutics For Gastrointestinal DiseaseK08DK134856 · NIDDK · STANFORD UNIVERSITY · PI Sean Paul Spencer · 2023 to 2026
$664k
NCATS NIH HHS UM1 TR004921NIDDK NIH HHS K08 DK134856NIDDK NIH HHS L30 DK126220NIDDK NIH HHS R01 DK085025NIDDK NIH HHS T32 DK007056
6 · The paper itself

Abstract

In healthy individuals, short cycles of a fasting-mimicking diet (FMD) decrease systemic inflammatory markers and improve metabolic health. Potential benefits of FMD have not been investigated in Crohn's disease (CD). We conducted an open-label, randomized, controlled trial to assess the effects of FMD in adults with mild-to-moderate CD. Patients in the FMD group followed an FMD for five consecutive days per month for three consecutive months, returning to their regular baseline diet on non-FMD days. Control participants continued their baseline diet. The primary outcome of clinical response was a reduction in CD Activity Index (CDAI) of at least 70 points or CDAI of ≤150 after the third 5-day diet cycle. Forty-five patients in the FMD group (69.2%) and 14 patients in the control group (43.8%) met the primary outcome of clinical response (P = 0.03). Forty-two patients in the FMD group (64.6%) and 12 patients in the control group (37.5%) achieved the secondary outcome of clinical remission (P = 0.02). There was also a decline from baseline in fecal calprotectin (an inflammatory marker) in the FMD group compared with the control group (-22.0% versus 8.0%, P = 0.03). Exploratory analyses of plasma metabolites and peripheral blood mononuclear cell gene expression revealed post-FMD decreases in key inflammatory lipid mediators and immune-effector transcripts, concordant with reduced CD activity. Together, these findings demonstrate that FMD is superior to a baseline diet for inducing clinical response, clinical remission and biochemical improvement in mild-to-moderate CD, and support further investigation of FMD as an adjunctive therapy for chronic inflammatory diseases. ClinicalTrials.gov registration: NCT04147585 .

Indexed as

Crohn DiseaseDietFastingAdultBiomarkersFecesFemaleHumansLeukocyte L1 Antigen ComplexMaleMiddle AgedYoung AdultBiomarkersLeukocyte L1 Antigen Complex

Identifiers

PMID41530382
PMCPMC13293041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.